Cambrian Biopharma is the largest investor in cancer immunotherapy developer Sensei Biotherapeutics, which has filed to raise up to $100m.
Sensei Biotherapeutics, a US-based oncology treatment developer backed by medical research group Cambrian Biopharma, has filed for a $100m initial public offering on the Nasdaq Global Market. Founded in 1999, Sensei is developing immunotherapies to treat cancer and will put part of the IPO proceeds into an ongoing phase 1/2 clinical trial for its lead…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.